Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome

Open access
Szapary, Philippe O., Bloedon, LeAnne T., Samaha, Frederick F., Duffy, Danielle, Wolfe, Megan L., Soffer, Daniel, Reilly, Muredach P., Chittams, Jesse, Rader, Daniel J. · 2006 · Arteriosclerosis, Thrombosis, and Vascular Biology

Abstract

Objective— The purpose of this research was to evaluate the short-term effects of pioglitazone (PIO) on high-density lipoprotein cholesterol (HDL-C) and other metabolic parameters in nondiabetic patients with metabolic syndrome (MetSyn). Methods and Results— Sixty nondiabetic adults with low HDL-C and MetSyn were randomized to PIO or matching placebo for 12 weeks. PIO increased HDL-C by 15% and 14% at 6 and 12 weeks, respectively, compared with placebo ( P <0.001). Changes in HDL-C were correlated to changes in adiponectin ( r =0.34; P =0.01) but not to changes in insulin resistance. PIO did not affect serum triglycerides or low-density lipoprotein (LDL) cholesterol concentrations but reduced the number of small LDL particles by 18% ( P <0.001). PIO reduced median C-reactive protein levels by 31% ( P <0.001) and mean resistin levels by 10% ( P =0.02) while increasing mean serum levels of adiponectin by 111% ( P <0.001) compared with placebo. PIO did not affect weight and modestly decreased insulin resistance. Conclusions— In nondiabetic patients with low HDL-C and MetSyn, PIO significantly raised HDL-C and favorably affected lipoprotein particle size, markers of inflammation, and adipokines without changes in triglycerides, LDL-C, or weight. These results suggest that PIO has direct effects on HDL, which may contribute to its antiatherogenic effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.atv.0000195790.24531.4f

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 162

Metadata

Authors
Szapary, P. O., Bloedon, L. T., Samaha, F. F., Duffy, D., Wolfe, M. L., Soffer, D., Reilly, M. P., Chittams, J., & Rader, D. J.
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Published
2006-01
Volume
26
Issue
1
Pages
182-188
ISSN
  • 1079-5642 (ISSN-L)
  • 1524-4636
OpenAlex
W2018176172
Cited by
162
References
7
FWCI
17.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome. https://app.cochat.ai/papers/10.1161/01.atv.0000195790.24531.4f
The paper
Szapary, P. O., Bloedon, L. T., Samaha, F. F., Duffy, D., Wolfe, M. L., Soffer, D., Reilly, M. P., Chittams, J., & Rader, D. J. (2006). Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.0000195790.24531.4f

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.